Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

L.A. McKeown

February 01, 2024

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

CV Risk Disparities by Race/Ethnicity Persist in Childhood Cancer Survivors

Yael L. Maxwell

April 13, 2023

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

News Features

Top News in Heart Failure: 2018

Shelley Wood

December 28, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Michael O'Riordan

February 20, 2018

News Conference News AHA 2012

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Jason Kahn

November 11, 2012

Advertisement

January 2025 Dispatch for the CV Team

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Semaglutide Has Similar Benefits in Women and Men With HFpEF

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

February 2024 Dispatch for the CV Team

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

CV Risk Disparities by Race/Ethnicity Persist in Childhood Cancer Survivors

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Dapagliflozin Boosts Health Status Across LVEF Range

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Top News in Heart Failure: 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content